Clinical Trials Logo

Clinical Trial Summary

The primary objective of this study is to describe and compare plasmatic anti-proteasome auto-antibody concentrations among three distinct groups: (1) patients suffering from bullous pemphigoide; (2) patients suffering from other dermatological auto-immune diseases; (3) an elderly control group.


Clinical Trial Description

The secondary objectives of this study are:

To compare the following parameters between the 3 groups:

- plasmatic proteasome concentrations

- plasmatic proteasome proteolytic activity

To explore the potential relationships between:

- plasmatic proteasome concentrations

- plasmatic proteasome proteolytic activity

- plasmatic anti-proteasome auto-antibody concentrations

- measures of disease severity for dermatological auto-immune diseases

To characterize plasmatic anti-proteasome auto-antibodies in patients suffering from bullous pemphigoide and other dermatological auto-immune diseases (other bullous auto immune diseases: pemphigus, cutaneous lupus, ...).

To characterize the expression and the activity of proteasomes in skin samples, in plasma and in circulating mononuclear cells in patients with bullous pemphigoide. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT01559155
Study type Observational
Source Centre Hospitalier Universitaire de Nimes
Contact
Status Terminated
Phase
Start date November 5, 2013
Completion date June 9, 2015

See also
  Status Clinical Trial Phase
Recruiting NCT05534776 - Validation of 5-Point Investigator Global Assessments for Pemphigus
Terminated NCT00278642 - Hematopoietic Stem Cell Support in Patients With Autoimmune Bullous Skin Disorders Phase 1
Not yet recruiting NCT05898308 - Comparison of a Personalized Maintenance Therapy With the Standard Treatment in Pemphigus Phase 4
Active, not recruiting NCT01974518 - Comparative Study of Rituximab Versus Combination of Rituximab and Intravenous Cyclophosphamide in Severe Pemphigus Phase 3
Recruiting NCT05284929 - Human Leukocyte Antigen Class II (DRB1 and DQB1) Alleles and Haplotypes Frequencies in Patients With Pemphigus Vulgaris Among the Russian Population
Recruiting NCT05954416 - FARD (RaDiCo Cohort) (RaDiCo-FARD)
Completed NCT00283712 - Use of Infliximab for the Treatment of Pemphigus Vulgaris Phase 2
Not yet recruiting NCT06285435 - Coagulation Activation in Patients With Pemphigus
Not yet recruiting NCT06454357 - A Clinical Study of B007 in the Treatment of Pemphigus. Phase 2/Phase 3
Completed NCT01299857 - Long-term Clinical and Biological Evaluation of Patients With Severe Forms of Pemphigus Treated by Rituximab Phase 3
Completed NCT00960713 - The RITAI Cohort: An Observational Study on Rituximab Off-label Use for Auto-immune Disorders N/A
Completed NCT00213512 - Effect of Anti CD20 in Pemphigus Desease Phase 2/Phase 3
Active, not recruiting NCT04400994 - IVIG With Rituximab vs Rituximab as First Line Treatment of Pemphigus Phase 2
Recruiting NCT02237313 - Identification of Vulnerability Factors in the Course of Pemphigus Patients N/A
Terminated NCT03075904 - A Safety and Dose-Finding Study of SYNT001 in Subjects With Pemphigus (Vulgaris or Foliaceus) Phase 1/Phase 2
Terminated NCT03762265 - A Study of PRN1008 in Patients With Pemphigus Phase 3
Recruiting NCT02365675 - Wound Dressings for Pemphigus and Pemphigoid N/A
Recruiting NCT01338103 - Treatment of Pemphigus Patients With Rituximab 1000mgX2 and Assessment of Immune Status Via Cylex N/A
Active, not recruiting NCT00656656 - Immunoadsorption, Dexamethasone Pulse Therapy and Rituximab for Pemphigus Phase 2
Completed NCT00127764 - European Trial of Adjuvant Oral Glucocorticoid Pulse Therapy in Pemphigus Phase 2/Phase 3